Science simplified

Miroculus is a San Francisco-based biotechnology company, transforming the medical industry and life science with its innovative approach to disease detection. Through its revolutionary portable lab, Miroculus empowers thousands of scientists, engineers, hospitals and lab operators all over the world to create, share, download and run the most complex protocols and tests in a fully automated fashion. Miroculus has developed a proprietary technology — Miro technology — based on digital microfluidics to automate and miniaturize genomic protocols such as Next Generation Sequencing library preparation, synthetic biology, cell editing, and combinatorial chemistry, in a compact, user-friendly system. Miroculus IP extends to over 25 patent applications within 13 different patent families. In addition to its groundbreaking technology, the company is also dedicated to making its device accessible to a wider range of patients globally through establishing partnerships with healthcare providers and institutions around the world. To date, the company has raised over $45 million to move its vision forward, from notable investors in the space, including Cota Capital and Section 32.

The company has raised funds higher than 39$ million from venture capital firms (OSFund, Nazca), family offices, and companies on the Fortune 500 list. In 2018, Miroculus was co-financed by Endeavor Catalyst as well and recently closed its Series B financing round amounting to 45$ million, with Cota Capital and Section 32 participating in the expansion of financing, aiming at the market exit of its impressive Miro Canvas device. In 2023, the company was acquired by Integra Biosciences.